Our Clinical Product Portfolio

Leveraging our technical expertise in structure-based drug design and our innovative drug discovery engine, we have developed a diverse pipeline with 8 drug candidates that are in clinical development, with 20 ongoing clinical studies and 18 INDs filed globally. Below is an overview of our pipeline:

Candidate Mechanism Lead Indications Preclinical Phase I Phase II/III Market Rights
Apoptosis Targeted Compounds
APG-1252 Bcl-2/Bcl-xL Cancer (SCLC, lymphoma)
Global
APG-2575 Bcl-2 Selective Blood Cancer
Global
AT-101 Bcl-2/Bcl-xL/Mcl-1 CLL
Global
APG-1387 IAP Dimer Solid Tumors
Global
IO Combo
Global
Hepatitis B
Global
APG-115 MDM2-p53 Solid Tumors
Global
Chemotherapy combo (Salivary Gland Carcinoma)
Global
IO Combo
Global
Dry AMD
Global
Next-Generation Kinase Inhibitors
HQP1351(1) BCR-ABL Mutant Resistant CML
Global
KIT GIST
Global
HQP8361(2) c-Met Selective Cancer (c-Met+)
Australia, Japan, Greater China
APG-2449 FAK Cancer
(FAK, ALK, Ros)
Global
Age-Related Diseases
Bcl-2 related The Company has a strategic relationship with Unity related to Unity’s development of senolytic drugs. Joint venture in Greater China
  1. HQP1351, also known as GZD824 and D824, was licensed from Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.
  2. HQP8361, developed by our wholly owned subsidiary Healthquest Pharma, also known as MK8033, was in-licensed from MSD.